SGI-110 Priming Sensitizes Hepatocellular Carcinoma Cells to Oxaliplatin
Promoter DNA hypermethylation is an important biomarker of hepatocellular carcinoma (HCC), supporting the potential utility of demethylating agents in this disease. SGI-110 is a second-generation hypomethylating agent formulated as a dinucleotide of decitabine and deoxyguanosine that yields longer half-life and more extended decitabine exposure than decitabine IV infusion. Here we performed preclinical evaluation of SGI-110 in HCC models to guide the design of a phase I/II clinical trial. HCC cell lines and xenograft models were used to determine the antitumor activity of SGI-110 as a single agent and in combination with oxaliplatin.
Source: Molecular Oncology - Category: Cancer & Oncology Authors: Yuting Kuang, Anthony El-Khoueiry, Pietro Taverna, Mats Ljungman, Nouri Neamati Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Eloxatin | Hepatocellular Carcinoma | Liver Cancer